Clinical value of the SorCS1 gene promoter methylation determination in patients with colorectal cancer

doi:10.3969/j.issn.1673-8640.2022.04.006

Abstract

Abstract:

Objective To investigate the clinical value of the SorCS1 gene promoter methylation determination in patients with colorectal cancer. Methods Cancer and adjacent tissues from 17 colorectal cancer patients were collected. The MassARRAY platform was used to determine the levels of gene promoter methylation in cancer tissues and adjacent tissues of patients with colorectal cancer,and the genes with different promoter methylation between cancer tissues and adjacent tissues were screened out and then compared with the Cancer Genome Atlasc（TCGA） database. Meanwhile,the methylation levels of SEPT9 gene were determined. The difference （Δ） determined by subtracting the determination value of gene promoter methylation in adjacent tissue from that in cancer tissue indicated the difference. Results A total of 2 genes（SorCS1 and CASR） were screened out. The levels of SorCS1,CASR and SEPT9 methylation in colorectal cancer tissues were higher than those in adjacent cancer tissues（P<0.001）. The comparison with TCGA database revealed that the expressions of SorCS1 gene were lower in patients with bladder urothelial carcinoma,cervical squamous cell carcinoma,colon adenocarcinoma,glioblastoma multiforme,rectum adenocarcinoma and stomach adenocarcinoma than that in healthy controls（P<0.05）,while the promoter methylation level of SorCS1 gene was higher in colon adenocarcinoma,rectum adenocarcinoma and lung adenocarcinoma than that in healthy controls（P<0.05）. The difference of CASR gene expression between colorectal cancer patients and healthy controls was not statistically significant（P>0.05）,and the data of CASR gene promoter methylation was not available in TCGA database. The differences between ΔSorCS1 and SEPT9 gene promoter methylation levels in colorectal cancer patients were associated with tumor stage,and those in progression stage（Ⅲ-Ⅳ） were higher than those in early stage（Ⅰ-Ⅱ）（P<0.05）. The gene promoter methylation differences were also associated with lymph node metastasis,and the higher level of ΔSorCS1 and SEPT9 gene promoter methylation levels appeared in the group of lymph nodes with metastasis than those without metastasis（P<0.05）,independent of sex,age,tumor site and maximum diameter of tumors（P>0.05）. However,there was no statistical significance in ΔCASR between different clinicopathological characteristics of patients（P>0.05）. The positive rate of SorCS1 gene methylation was 82.35%（14/17）,while that of SEPT9 gene methylation was 70.58%（12/17）,respectively. The positive rate of combined determination was 88.24%（15/17）. Conclusions SorCS1 gene promoter methylation determination has a high positive rate in colorectal cancer patients,and it is complementary to SEPT9 gene promoter methylation,which can be a potential new molecular marker for colorectal cancer development.

Key words: SorCS1, SEPT9, Methylation, Colorectal cancer

CLC Number:

R446.7

LIU Kai, ZHANG Peiru, XIE Suhong, GUO Lin, LU Renquan. Clinical value of the SorCS1 gene promoter methylation determination in patients with colorectal cancer[J]. Laboratory Medicine, 2022, 37(4): 330-335.

Figures/Tables 4

References 24

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI URL
[2]	ARNOLD M, SIERRA M S, LAVERSANNE M, et al. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut, 2017, 66(4):683-691. DOI URL
[3]	WANG Y, CHEN P M, LIU R B. Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection[J]. World J Gastrointest Oncol, 2018, 10(1):15-22. DOI URL
[4]	JONES P A. Functions of DNA methylation:islands,start sites,gene bodies and beyond[J]. Nat Rev Genet, 2012, 13(7):484-492.
[5]	MAHUL B A, STEPHEN E, FREDERICK L G, et al. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2016.
[6]	SONG L, CHEN Y, GONG Y, et al. Opportunistic screening and survival prediction of digestive cancers by the combination of blood mSEPT9 with protein markers[J]. Ther Adv Med Oncol, 2020, 12:1758835920962966.
[7]	TÓTH K, GALAMB O, SPISÁK S, et al. The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer[J]. Pathol Oncol Res, 2011, 17(3):503-509. DOI URL
[8]	CHURCH T R, WANDELL M, LOFTON-DAY C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut, 2014, 63(2):317-325. DOI URL
[9]	柏愚, 杨帆, 马丹, 等. 中国早期结直肠癌筛查及内镜诊治指南(2014年,北京)[J]. 胃肠病学, 2015, 20(6):345-365.
[10]	SUBKHANGULOVA A, MALIK A R, HERMEY G, et al. SORCS1 and SORCS3 control energy balance and orexigenic peptide production[J]. EMBO Rep, 2018, 19(4):e44810.
[11]	RIBEIRO L F, VERPOORT B, NYS J, et al. SorCS1-mediated sorting in dendrites maintains neurexin axonal surface polarization required for synaptic function[J]. PLoS Biol, 2019, 17(10):e3000466.
[12]	REITZ C, TOKUHIRO S, CLARK L N, et al. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk[J]. Ann Neurol, 2011, 69(1):47-64. DOI URL
[13]	GOODARZI M O, LEHMAN D M, TAYLOR K D, et al. SORCS1:a novel human type 2 diabetes susceptibility gene suggested by the mouse[J]. Diabetes, 2007, 56(7):1922-1999. DOI URL
[14]	LAZAR J, O'MEARA C C, SARKIS A B, et al. SORCS1 contributes to the development of renal disease in rats and humans[J]. Physiol Genomics, 2013, 45(16):720-728. DOI URL
[15]	HUANG P Z, PENG S Y, YU H C, et al. Decreased expression of SorCS1 in colorectal cancer:an independent predictor of poor prognosis[J]. Neoplasma, 2020, 67(1):119-128. DOI URL
[16]	ROSELLI S, PUNDAVELA J, DEMONT Y, et al. Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion[J]. Oncotarget, 2015, 6(12):10473-10486. DOI URL
[17]	GHAEMIMANESH F, AHMADIAN G, TALEBI S, et al. The effect of sortilin silencing on ovarian carcinoma cells[J]. Avicenna J Med Biotechnol, 2014, 6(3):169-177.
[18]	ABDUL AZIZ N A, MOKHTAR N M, HARUN R, et al. A 19-gene expression signature as a predictor of survival in colorectal cancer[J]. BMC Med Genomics, 2016, 9(1):58. DOI URL
[19]	SCHNEIDER B G, MERA R, PIAZUELO M B, et al. DNA methylation predicts progression of human gastric lesions[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(10):1607-1613. DOI URL
[20]	LARSEN J V, HERMEY G, SØRENSEN E S, et al. Human sorCS1 binds sortilin and hampers its cellular functions[J]. Biochem J, 2014, 457(2):277-288. DOI URL
[21]	SAVAS J N, RIBEIRO L F, WIERDA K D, et al. The sorting receptor SorCS1 regulates trafficking of neurexin and AMPA receptors[J]. Neuron, 2015, 87(4):764-780. DOI URL
[22]	LARSEN J V, KRISTENSEN A M, PALLESEN L T, et al. Cytokine-like factor 1,an essential facilitator of cardiotrophin-like cytokine:ciliary neurotrophic factor receptor α signaling and sorLA-mediated turnover[J]. Mol Cell Biol, 2016, 36(8):1272-1286. DOI URL
[23]	李丹, 苏光建, 肖燕萍, 等. 外周血甲基化Septin-9检测对结直肠癌诊断价值的Meta分析[J]. 中国免疫学杂志, 2017, 33(10):1547-1551.
[24]	BERGHEIM J, SEMAAN A, GEVENSLEBEN H, et al. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer:a prospective observational cohort study[J]. Br J Cancer, 2018, 118(9):1217-1228. DOI URL

组织类型	例数	SEPT9基因启动子甲基化（ΔΔCt）
癌组织	17	5.170（4.015~5.510）
癌旁组织	17	1.210（1.445~2.410）
Z值		-3.243
P值		<0.001

组织类型	例数	SEPT9基因启动子甲基化（ΔΔCt）
癌组织	17	5.170（4.015~5.510）
癌旁组织	17	1.210（1.445~2.410）
Z值		-3.243
P值		<0.001

病理特征	例数	ΔSorCS1基因	ΔCASR基因	SEPT9基因
性别
男性	9	0.330（0.205~0.545）	0.280（0.075~0.440）	31.779（4.509~109.597）
女性	8	0.425（0.253~0.488）	0.245（0.225~0.500）	17.380（4.065~81.032）
U值		30.500	33.500	36.000
P值		0.606	0.810	1.000
年龄
≤60岁	7	0.290（0.150~0.480）	0.280（0.030~0.540）	7.890（1.376~77.708）
>60岁	10	0.445（0.300~0.543）	0.225（0.080~0.415）	39.478（4.650~226.364）
U值		48.500	33.500	24.000
P值		0.193	0.884	0.283
肿瘤分期
Ⅰ~Ⅱ	4	0.205（0.143~0.283）	0.235（0.070~0.355）	2.802（0.401~5.797）
Ⅲ~Ⅳ	13	0.480（0.325~0.520）	0.300（0.070~0.515）	47.177（8.508~116.131）
U值		46.000	21.500	3.000
P值		0.023	0.610	0.009
淋巴结转移
无	8	0.275（0.173~0.443）	0.145（0.008~0.475）	6.340（2.436~41.102）
有	9	0.490（0.360~0.545）	0.380（0.120~0.440）	82.139（25.634~455.087）
U值		56.500	25.000	21.000
P值		0.046	0.290	0.015
病理特征	例数	ΔSorCS1基因	ΔCASR基因	EPT9基因
肿瘤部位
直肠	10	0.400（0.218~0.513）	0.285（0.075~0.550）	8.508（2.612~41.791）
结肠	7	0.400（0.260~0.500）	0.280（0.050~0.380）	69.071（4.509~302.605）
U值		33.500	27.500	10.000
P值		0.887	0.464	0.149
肿瘤直径^①
≤5 cm	12	0.345（0.173~0.498）	0.290（0.045~0.528）	8.508（3.149~75.549）
>5 cm	4	0.390（0.323~0.518）	0.240（0.063~0.388）	64.658（15.387~783.230）
U值		30.000	22.500	14.000
P值		0.521	0.856	0.225

病理特征	例数	ΔSorCS1基因	ΔCASR基因	SEPT9基因
性别
男性	9	0.330（0.205~0.545）	0.280（0.075~0.440）	31.779（4.509~109.597）
女性	8	0.425（0.253~0.488）	0.245（0.225~0.500）	17.380（4.065~81.032）
U值		30.500	33.500	36.000
P值		0.606	0.810	1.000
年龄
≤60岁	7	0.290（0.150~0.480）	0.280（0.030~0.540）	7.890（1.376~77.708）
>60岁	10	0.445（0.300~0.543）	0.225（0.080~0.415）	39.478（4.650~226.364）
U值		48.500	33.500	24.000
P值		0.193	0.884	0.283
肿瘤分期
Ⅰ~Ⅱ	4	0.205（0.143~0.283）	0.235（0.070~0.355）	2.802（0.401~5.797）
Ⅲ~Ⅳ	13	0.480（0.325~0.520）	0.300（0.070~0.515）	47.177（8.508~116.131）
U值		46.000	21.500	3.000
P值		0.023	0.610	0.009
淋巴结转移
无	8	0.275（0.173~0.443）	0.145（0.008~0.475）	6.340（2.436~41.102）
有	9	0.490（0.360~0.545）	0.380（0.120~0.440）	82.139（25.634~455.087）
U值		56.500	25.000	21.000
P值		0.046	0.290	0.015
病理特征	例数	ΔSorCS1基因	ΔCASR基因	EPT9基因
肿瘤部位
直肠	10	0.400（0.218~0.513）	0.285（0.075~0.550）	8.508（2.612~41.791）
结肠	7	0.400（0.260~0.500）	0.280（0.050~0.380）	69.071（4.509~302.605）
U值		33.500	27.500	10.000
P值		0.887	0.464	0.149
肿瘤直径^①
≤5 cm	12	0.345（0.173~0.498）	0.290（0.045~0.528）	8.508（3.149~75.549）
>5 cm	4	0.390（0.323~0.518）	0.240（0.063~0.388）	64.658（15.387~783.230）
U值		30.000	22.500	14.000
P值		0.521	0.856	0.225